X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
Other Certificates
0
Other Suppliers
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
Details:
The proceeds will be utilized for the preparation of Stalicla’s pioneering precision Autism Spectrum Disorder (ASD) Phase 2 trial evaluating STP1, a fixed dose combination of PDE4/3 inhibitor (ibudilast) and NKCC1 antagonist (bumetanide).
Lead Product(s): Ibudilast,Bumetanide
Therapeutic Area: Neurology Product Name: STP1
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: SPRIM Global Investments
Deal Size: $17.4 million Upfront Cash: Undisclosed
Deal Type: Series B Financing January 16, 2024
Details:
MN-166 (ibudilast) is a small molecule compound that inhibits phosphodiesterase type-4 (PDE4) and Migration inhibitory factor. It is in late-stage clinical development for the treatment of chlorine gas-induced lung damage such as ARDS and acute lung injury.
Lead Product(s): Ibudilast
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: MN 166
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: BARDA
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 27, 2023
Details:
STALICLA and Firefly will leverage their technological platforms including the DEPI and BNA platform respectively to further advance EEG validation in two upcoming Phase 2 clinical trials including STALICLA’s lead asset STP1, a tailored treatment candidate for ASD-Phenotype 1.
Lead Product(s): Ibudilast,Bumetanide
Therapeutic Area: Neurology Product Name: STP1
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Firefly Neuroscience
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership March 27, 2023
Details:
MN-166 (ibudilast) is a small molecule compound that inhibits phosphodiesterase type-4 (PDE4) and inflammatory cytokines, including macrophage migration inhibitory factor (MIF).
Lead Product(s): Ibudilast
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: MN-166
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: BARDA
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership March 09, 2023
Details:
MN-166 (ibudilast) is a small molecule compound that inhibits phosphodiesterase type-4 (PDE4) and inflammatory cytokines, including macrophage migration inhibitory factor (MIF). It is in late-stage clinical development for the treatment of neurodegenerative diseases.
Lead Product(s): Ibudilast
Therapeutic Area: Infections and Infectious Diseases Product Name: MN-166
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 08, 2023
Details:
MN-166 (ibudilast) is a small molecule compound that inhibits phosphodiesterase type-4 (PDE4) and inflammatory cytokines, including macrophage migration inhibitory factor (MIF). It is in late-stage clinical development for the treatment of neurodegenerative diseases.
Lead Product(s): Ibudilast
Therapeutic Area: Psychiatry/Psychology Product Name: MN 166
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 30, 2023
Details:
MN-166 (ibudilast) is a small molecule compound that inhibits phosphodiesterase type-4 (PDE4) and inflammatory cytokines, including macrophage migration inhibitory factor (MIF). It is in late-stage clinical development for the treatment of neurodegenerative diseases.
Lead Product(s): Ibudilast,Temozolomide
Therapeutic Area: Oncology Product Name: MN-166
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 12, 2023
Details:
MN-166 (Ibudilast) is a small molecule compound that inhibits phosphodiesterase type-4 (PDE4) and inflammatory cytokines, including macrophage migration inhibitory factor (MIF). It is in late-stage clinical development for the treatment of neurodegenerative diseases.
Lead Product(s): Ibudilast
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: MN-166
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 05, 2023
Details:
MN-166 (ibudilast) is a small molecule compound that inhibits phosphodiesterase type-4 (PDE4) and inflammatory cytokines, including macrophage migration inhibitory factor (MIF).
Lead Product(s): Ibudilast
Therapeutic Area: Psychiatry/Psychology Product Name: MN-166
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 05, 2022
Details:
MN-166 (ibudilast) is a small molecule compound that inhibits phosphodiesterase type-4 (PDE4) and inflammatory cytokines, including macrophage migration inhibitory factor (MIF).
Lead Product(s): Ibudilast,Temozolomide
Therapeutic Area: Oncology Product Name: MN-166
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 13, 2022
Details:
MN-166 (ibudilast) is a small molecule compound that inhibits phosphodiesterase type-4 (PDE4) and inflammatory cytokines, including macrophage migration inhibitory factor (MIF).
Lead Product(s): Ibudilast
Therapeutic Area: Infections and Infectious Diseases Product Name: MN-166
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: University Health Network
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement August 16, 2022
Details:
MN-166 (ibudilast) is a small molecule compound that inhibits phosphodiesterase type-4 (PDE4) and inflammatory cytokines, including macrophage migration inhibitory factor (MIF).
Lead Product(s): Ibudilast
Therapeutic Area: Neurology Product Name: MN-166
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 21, 2022
Details:
MN-166 (ibudilast) is a small molecule compound that inhibits phosphodiesterase type-4 (PDE4) and inflammatory cytokines, including macrophage migration inhibitory factor (MIF).
Lead Product(s): Ibudilast
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: MN-166
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 29, 2022
Details:
MN-166 (ibudilast) is a small molecule compound that inhibits phosphodiesterase type-4 (PDE4) and inflammatory cytokines, including macrophage migration inhibitory factor (MIF).
Lead Product(s): Ibudilast
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: MN-166
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 08, 2022
Details:
MN-166 (ibudilast) is a small molecule compound that inhibits phosphodiesterase type-4 (PDE4) and inflammatory cytokines, including macrophage migration inhibitory factor (MIF).
Lead Product(s): Ibudilast
Therapeutic Area: Neurology Product Name: MN-166
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 21, 2022
Details:
The MIF inhibitor MN-166 (ibudilast) in preclincal studies, dramatically inhibited UM cell migration (p<0.001), suggesting that MIF plays a major role in the cell-to-cell cross-talk, for the treatment of neurodegenerative diseases.
Lead Product(s): Ibudilast
Therapeutic Area: Oncology Product Name: MN-166
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 20, 2022
Details:
The primary analysis of this Phase 2 clinical trial showed that MN-166 reduced alcohol craving on non-drinking days (p=0.02), reduced the odds of heavy drinking by 45% (p=0.04), and attenuated neural response to alcohol cues (p=0.01).
Lead Product(s): Ibudilast
Therapeutic Area: Psychiatry/Psychology Product Name: MN-166
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 07, 2022
Details:
MN-166 (ibudilast) is a small molecule compound that inhibits phosphodiesterase type-4 (PDE4) and inflammatory cytokines, including macrophage migration inhibitory factor (MIF). MN-166 (ibudilast) is being evaluated in patients that are at risk for developing ARDS.
Lead Product(s): Ibudilast
Therapeutic Area: Psychiatry/Psychology Product Name: MN-166
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 27, 2022
Details:
After mice are exposed to chlorine gas and treated with MN-166 (ibudilast) or control, the study will evaluate survival, clinical outcomes, body weights, lung weights, and upper respiratory tract histopathology.
Lead Product(s): Ibudilast
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: MN-166
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: BARDA
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership June 28, 2021
Details:
The allowed claims cover the combination of MN-166 (ibudilast) and riluzole for use in a method of treating a patient with ALS wherein the treatment results in stabilization of the patient’s scleroses state.
Lead Product(s): Ibudilast,Riluzole
Therapeutic Area: Neurology Product Name: MN-166
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 05, 2021
Details:
MediciNova has received a Notice of Allowance from the Japan Patent Office for a pending patent application which covers the combination of MN-166 (ibudilast) and riluzole for the treatment of amyotrophic lateral sclerosis (ALS).
Lead Product(s): Ibudilast,Riluzole
Therapeutic Area: Neurology Product Name: MN-166
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 18, 2021
Details:
The allowed claims cover a method of alleviating the negative effects of progressive multiple sclerosis, treating progressive multiple sclerosis, or slowing the progression of progressive multiple sclerosis by administering MN-166 and interferon-beta in separate dosage forms.
Lead Product(s): Ibudilast,Interferon-beta
Therapeutic Area: Immunology Product Name: MN-166
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 29, 2020
Details:
The proposed clinical trial will evaluate MN-166 (ibudilast) as a potential treatment to reduce acute neurotoxicity severity and CIPN in patients with metastatic colorectal cancer.
Lead Product(s): Ibudilast
Therapeutic Area: Neurology Product Name: MN-166
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Medicinova
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration October 22, 2020
Details:
This study was a randomized, double-blind, placebo-controlled Phase 2 trial to evaluate the effect of 14 days of ibudilast treatment on heavy drinking days and alcohol neural cue reactivity.
Lead Product(s): Ibudilast
Therapeutic Area: Psychiatry/Psychology Product Name: MN-166
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: UCLA
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 06, 2020
Details:
This new patent has improved therapeutic claims compared to the first patent which covers MN-166 (ibudilast) for the treatment of glioblastoma.
Lead Product(s): Ibudilast,Temozolomide
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 20, 2020
Details:
MediciNova will initiate a clinical trial of MN-166 (ibudilast) for acute respiratory distress syndrome (ARDS) caused by COVID-19 (Coronavirus Disease 2019).
Lead Product(s): Ibudilast
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 08, 2020
Details:
MediciNova’s decision to pursue development of this indication was based on positive results of a recent preclinical study in an animal model of ARDS.
Lead Product(s): Ibudilast
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 09, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
